AcrIIIA1 binds to Csm2 to attenuate Cas10's DNase activity and associates with RNAs that target accessory nucleases, providing robust protection against Type III CRISPR-Cas immunity.
AcrIIIA1 is the first identified Type III-A specific anti-CRISPR protein that, along with associated RNAs, targets core Cas and accessory nucleases to subvert CRISPR-Cas immunity.
Clustered regularly-interspaced short palindromic repeats (CRISPRs) and CRISPR-associated (Cas) proteins protect bacteria and archaea from their viruses, and anti-CRISPRs (Acrs) are small virus-encoded proteins that inhibit CRISPR-Cas immunity. Over 80 families of Acrs have been described to date; however, only three of these subvert Type III CRISPR-Cas immunity. Type III systems employ a complex network of Cas and accessory nucleases to degrade viral nucleic acids. Here, we discover and characterize AcrIIIA1, the first Type III-A specific anti-CRISPR protein. We demonstrate that AcrIIIA1 binds to Csm2 within the Cas10-Csm effector complex and attenuates Cas10's DNase activity and second messenger production. Additionally, AcrIIIA1 associates with fragmented t(m)RNAs (acrIIIA1-RNAs), and we show that they co-purify with the Cas10-Csm complex during phage infection. Although the precise role(s) of acrIIIA1-RNAs remain unclear, we found that they bind stably to RNase R, a host-encoded nuclease known to bolster immunity, and RNase R has the capacity to degrade them. Altogether, our results support a model in which AcrIIIA1 and its associated RNAs target both core Cas and accessory nucleases to provide robust protection against Type III CRISPR-Cas immunity.
Chou-Zheng et al. (Mon,) conducted a other in Type III CRISPR-Cas immunity. AcrIIIA1 was evaluated. AcrIIIA1 binds to Csm2 to attenuate Cas10's DNase activity and associates with RNAs that target accessory nucleases, providing robust protection against Type III CRISPR-Cas immunity.